The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale

Galer, Bradley S.; Jensen, Mark P.; Ma, Tina; Davies, Pamela Stitzlein; Rowbotham, Michael C.

doi:10.1097/00002508-200209000-00004

Cited by 223 publications

(132 citation statements)

References 7 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported that systemic administration of lidocaine decreases ectopic activity recorded from injured peripheral sensory fibers (Chabal et al, 1989;Devor et al,1992;Omana-Zapata et al,1997a;Sotgiu et al, 1992) and reduces neuropathic pain (Brochu et al, 2006;Erichsen et al, 2003;Sinnott et al, 1999;Smith et al, 2002). Furthermore, systematic reviews of human studies using systemic administration of local anesthetic drugs support their use for neuropathic pain (Kalso et al, 1998) and, in addition, topical or local administration of antidepressants (Lynch et al, 2005;McCleane, 2000) and local anesthetics (Abram, 2000;Galer et al, 1999;Galer, 2002;Galer et al, 2002;Herrmann et al, 2005;Khaliq et al, 2007;Koltzenburg et al, 1994;Meier et al, 2003;Nystrom and Hagbarth, 1981;Roganovic and Mandic-Gajic, 2006;Rowbotham et al, 1996;Varrassi et al, 2006;Vranken et al, 2002) have been demonstrated to be effective in treating neuropathic pain in controlled clinical trials.…”

Section: Contribution Of Peripheral Drive To Spontaneous Activity Of mentioning

confidence: 99%

Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy

Pitcher

Henry

2008

Experimental Neurology

View full text Add to dashboard Cite

Previously we reported that the cuff model of peripheral neuropathy, in which a 2 mm polyethylene tube is implanted around the sciatic nerve, exhibits aspects of neuropathic pain behavior in rats similar to those in humans and causes robust hyperexcitation of spinal nociceptive dorsal horn neurons. The mechanisms mediating this increased excitation are not known and remain a key unresolved question in models of peripheral neuropathy. In anesthetized adult male Sprague-Dawley rats 2-6 weeks after cuff implantation we found that elevated discharge rate of single lumbar (L 3-4 ) wide dynamic range (WDR) neurons persists despite acute spinal transection (T9) but is reversed by local conduction block of the cuff-implanted sciatic nerve; lidocaine applied distal to the cuff (i.e. between the cuff and the cutaneous receptive field) decreased spontaneous baseline discharge of WDR dorsal horn neurons ~40% (n=18) and when applied subsequently proximal to the cuff, i.e. between the cuff and the spinal cord, it further reduced spontaneous discharge by ~60% (n=19; P<0.05 proximal vs. distal) to a level that was not significantly different from that of naive rats. Furthermore, in cuff-implanted rats WDR neurons (n=5) responded to mechanical cutaneous stimulation with an exaggerated afterdischarge which was reversed entirely by proximal nerve conduction block. These results demonstrate that the hyperexcited state of spinal dorsal horn neurons observed in this model of peripheral neuropathy is not maintained by tonic descending facilitatory mechanisms. Rather, on-going afferent discharges originating from the sciatic nerve distal to, at, and proximal to the cuff maintain the synapticallymediated gain in discharge of spinal dorsal horn WDR neurons and hyperresponsiveness of these neurons to cutaneous stimulation. Our findings reveal that ectopic afferent activity from multiple regions along peripheral nerves may drive CNS changes and the symptoms of pain associated with peripheral neuropathy.

show abstract

Section: Contribution Of Peripheral Drive To Spontaneous Activity Of mentioning

confidence: 99%

Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy

Pitcher

Henry

2008

Experimental Neurology

View full text Add to dashboard Cite

show abstract

“…These plasma levels range from 0.13 to 0.23 μg/ml [259,260], which is approximately one-tenth of the effective level obtained with IVLT. Despite this, neuropathic pain patients achieve pain relief from topical lidocaine [259,[261][262][263][264][265][266][267]. Lidocaine patches also produce analgesia in patients with painful diabetic neuropathy [268], Complex regional pain syndrome (CRPS) [269] and non-neuropathic conditions such as osteoarthritis and low-back pain [261,[270][271][272][273].…”

Section: The Use Of Topical Lidocaine Therapy In Paediatric Chronic Painmentioning

confidence: 99%

A Review of Intravenous Lidocaine Infusion Therapy for Paediatric Acute and Chronic Pain Management

Lauder¹

2017

Pain Relief - From Analgesics to Alternative Therapies

View full text Add to dashboard Cite

Pediatric acute and chronic pain experiences involve the interaction of physiological, psychological, behavioural, developmental, pharmacological and situational factors. In the acute perioperative pain setting preventative multimodal analgesia is required to provide comfort and minimise the potential for "wind-up" and central sensitisation. When pain is recurrent, ongoing or chronic some children embark on a downward spiral of decreased physical, psychological and social functioning. The multidisciplinary team management approach is a well-established standard of care for children with complex chronic pain. Intravenous lidocaine has peripheral and central mediated analgesic, anti-inflammatory and anti-hyperalgesic properties. Intravenous lidocaine infusion therapy (IVLT) has been shown to be effective in the management of acute and chronic pain in adults. This chapter will present the rational for IVLT in pediatric pain management with emphasis on preventative multimodal therapy in acute pain and the multidisciplinary treatment approach in chronic pain. Large multi-centre randomised controlled trials are required to provide the evidence-base to confirm that IVLT is indeed an effective and safe treatment option in acute preventative multimodal analgesia and as an adjunct in the multidisciplinary care of chronic pain in the pediatric population. Keywords

show abstract

“…Long-term pain relief has been observed in clinical trials when lidocaine treatment was started within 2-3 weeks of post-herpetic neuralgia. [24] 2% lidocaine hydrochloride is also indicated for symptomatic relief of irritated or inflamed oral mucosa and pharynx. It is also useful for reducing gagging reflex during intraoral radiographic procedures and making dental impressions.…”

Section: Lidocainementioning

confidence: 99%

Topical drug delivery: An essential aid in the management of oral diseases

Shastry¹,

Sanjay²,

Kaul³

et al. 2015

JCRI

View full text Add to dashboard Cite

Topical medications play an important role in the management of oral lesions. Various topical medications ranging from topical anesthetics to topical antineoplastics have been widely used in dentistry. Topical medications have been extensively used as the first line of therapy in many conditions such as vesiculobullous diseases, oral infections like candidiasis, herpes simplex, potentially malignant disorders, neuropathic pain, and oral mucositis. Topical drug therapy provides targeted and a more efficient drug delivery options for the local oral lesions as compared to systemic therapy. While accessibility, lower systemic side effects, and many other advantages are associated with the usage of topical oral medications, several challenges are also faced such as taste alterations, poor penetration, and limited surface area. The objective of this review is to provide insight into the mechanism of topical drug delivery, summary of various topical medications used in oral lesions, advantages and disadvantages, characteristic of oral mucosa and various challenges faced in delivering topical medications.

show abstract

The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale

Cited by 223 publications

References 7 publications

Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy

Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy

A Review of Intravenous Lidocaine Infusion Therapy for Paediatric Acute and Chronic Pain Management

Topical drug delivery: An essential aid in the management of oral diseases

Contact Info

Product

Resources

About